MedTrace Logo

A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Seborrheic Dermatitis

NCT02749383 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2016-04-25

No results posted yet for this study

Summary

This study is a Phase II, single center, randomized, double-blind, placebo-controlled study in male and female subjects, aged ≥ 19 years with mild to moderate seborrheic dermatitis of the face. All subjects will receive BID topical applications of PAC-14028 cream or vehicle for up to 4 weeks.

Conditions

  • Seborrheic Dermatitis

Interventions

DRUG

PAC-14028 cream 0.3%

Topical application

DRUG

PAC-14028 cream 1.0%

Topical application

DRUG

PAC-14028 cream vehicle

Topical application

Sponsors & Collaborators

  • Amorepacific Corporation

    lead INDUSTRY

Principal Investigators

  • BeomJoon Kim, Professor · Department of Dermatology, Chungang University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-12-31
Completion
2015-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02749383 on ClinicalTrials.gov